B-71 Meningococcal Groups C and Y and *Haemophilus influenza* type b Tetanus Toxoid Vaccine — June 2013

MenHibrix® (HibMenCY-TT)

Vaccine	Age Licensed for Use	Administration and Schedule	Minimum Age for 1st Dose
MenHibrix® (HibMenCY-TT) ***(GlaxoSmithKline)***	6 weeks through 18 months of age	0.5 mL IM 2, 4, 6, and 12-15 months	6 weeks

MenHibrix® Vaccine Recommendations:

- MenHibrix is indicated for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroups C and Y and *Haemophilus influenza* type b
- MenHibrix is recommended ***only*** for infants at increased risk for meningococcal disease.
- Approved for use in children 6 weeks through 18 months of age
- Dosage is 0.5 mL given intramuscularly at 2, 4, 6, and 12-15 months of age
- The first dose may be given as early as 6 weeks of age
- The fourth dose may be given as late as 18 months of age
- MenHibrix may be co-administered with other routine infant vaccinations, including PCV13
- Infants and children (≥9 months) who have received MenHibrix and are traveling to areas with high endemic rates of meningococcal disease (such as the "meningitis belt") are not protected against serogroups A and W-135 and should receive a quadrivalent meningococcal conjugate vaccine (MCV4) before travel
- MenHibrix administration is indicated by a purple bar (range of recommended ages for certain high-risk groups) on the Recommended Immunization Schedule

*Infants at Increased Risk for Meningococcal Disease:

Infants with the following conditions are at increased risk of contracting meningococcal disease:

- persistent complement component deficiencies
- functional or anatomic asplenia
- sickle cell disease
- meningococcal serogroups C or Y disease outbreak environments

Contraindications

- Severe allergic reaction (e.g. anaphylaxis) after a previous dose of any meningococcal, *H. influenzae* type b, or tetanus toxoid-containing vaccine or any component of MenHibrix
- Delay vaccination for children with moderate or severe acute illnesses

Precautions

- Guillain-Barré syndrome occurrence within 6 weeks of receipt of a prior vaccine containing tetanus toxoid

Adverse Reactions

- **Injection site:** pain, redness, swelling
- **Systemic:** irritability, drowsiness, loss of appetite, fever

How Supplied/Storage and Handling

- Single-dose vials of powder vaccine (store refrigerated between 35° and 46°F (2° and 25°C)
- Vials of saline diluent (store refrigerated or in controlled room temperature (36°-77°F or 2°-25° C)

For more information on Meningococcal, Hib or any other recommended vaccines, visit the Immunization Program website at http://publichealth.lacounty.gov/ip/providers/B71.htm or call (213) 351-7800.